CD19-Targeted Immunotherapies for Diffuse Large B-Cell Lymphoma

Massimiliano Gambella, Simona Carlomagno, Anna Maria Raiola, Livia Giannoni, Chiara Ghiggi, Chiara Setti, Chiara Giordano, Silvia Luchetti, Alberto Serio, Alessandra Bo, Michela Falco, Mariella Della Chiesa, Emanuele Angelucci, Simona Sivori

Research output: Contribution to journalReview articlepeer-review


Surgical resection, chemotherapy and radiotherapy were, for many years, the only available cancer treatments. Recently, the use of immune checkpoint inhibitors and adoptive cell therapies has emerged as promising alternative. These cancer immunotherapies are aimed to support or harness the patient’s immune system to recognize and destroy cancer cells. Preclinical and clinical studies, based on the use of T cells and more recently NK cells genetically modified with chimeric antigen receptors retargeting the adoptive cell therapy towards tumor cells, have already shown remarkable results. In this review, we outline the latest highlights and progress in immunotherapies for the treatment of Diffuse Large B-cell Lymphoma (DLBCL) patients, focusing on CD19-targeted immunotherapies. We also discuss current clinical trials and opportunities of using immunotherapies to treat DLBCL patients.

Original languageEnglish
Article number837457
JournalFrontiers in Immunology
Publication statusPublished - Feb 24 2022


  • antibody-drug conjugates
  • bispecific T cell engagers
  • CAR-NK cells
  • CAR-T cells
  • engineered T cells
  • genetic modification
  • monoclonal antibodies

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'CD19-Targeted Immunotherapies for Diffuse Large B-Cell Lymphoma'. Together they form a unique fingerprint.

Cite this